BACKGROUND: In multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be classified by varying expression in normal tissue: restricted to testis, expressed in testis and brain and not restricted but selectively expressed in testis. DESIGN AND METHODS: Evaluation of cancer testis antigen expression was made in newly diagnosed multiple myeloma cases (HOVON-65/GMMG-HD4 trial; n = 320) and in relapse cases (APEX, SUMMIT, CREST trials; n = 264). Presence of expression using Affymetrix GeneChips was determined for 123 cancer testis antigens. Of these 87 had a frequency of more than 5% in the newly diagnosed and relapsed patients, and were evaluated in detail. RESULTS: Tissue restriction was known for 58 out of 87 cancer testis antigens. A significantly lower frequency of presence calls in the relapsed compared to newly diagnosed cases was found for 3 out of 13 testis restricted genes, 2 out of 7 testis/brain restricted genes, and 17 out of 38 testis selective genes. MAGEC1, MAGEB2 and SSX1 were the most frequent testis-restricted cancer testis antigens in both data sets. Multivariate analysis demonstrated that presence of MAGEA6 and CDCA1 were clearly associated with shorter progression free survival, and presence of MAGEA9 with shorter overall survival in the set of newly diagnosed cases. In the set of relapse cases, presence of CTAG2 was associated with shorter progression free survival and presence of SSX1 with shorter overall survival. CONCLUSIONS: Relapsed multiple myeloma reveals extensive cancer testis antigen expression. Cancer testis antigens are confirmed as useful prognostic markers in newly diagnosed multiple myeloma patients and in relapsed multiple myeloma patients. The HOVON-65/GMMG-HD4 trial is registered under Dutch trial register n. NTR-213. CREST, SUMMIT and APEX trials were registered under ns. M34100-024, M34100-025 and NCT00049478/NCT00048230, respectively.
RCT Entities:
BACKGROUND: In multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be classified by varying expression in normal tissue: restricted to testis, expressed in testis and brain and not restricted but selectively expressed in testis. DESIGN AND METHODS: Evaluation of cancer testis antigen expression was made in newly diagnosed multiple myeloma cases (HOVON-65/GMMG-HD4 trial; n = 320) and in relapse cases (APEX, SUMMIT, CREST trials; n = 264). Presence of expression using Affymetrix GeneChips was determined for 123 cancer testis antigens. Of these 87 had a frequency of more than 5% in the newly diagnosed and relapsed patients, and were evaluated in detail. RESULTS: Tissue restriction was known for 58 out of 87 cancer testis antigens. A significantly lower frequency of presence calls in the relapsed compared to newly diagnosed cases was found for 3 out of 13 testis restricted genes, 2 out of 7 testis/brain restricted genes, and 17 out of 38 testis selective genes. MAGEC1, MAGEB2 and SSX1 were the most frequent testis-restricted cancer testis antigens in both data sets. Multivariate analysis demonstrated that presence of MAGEA6 and CDCA1 were clearly associated with shorter progression free survival, and presence of MAGEA9 with shorter overall survival in the set of newly diagnosed cases. In the set of relapse cases, presence of CTAG2 was associated with shorter progression free survival and presence of SSX1 with shorter overall survival. CONCLUSIONS: Relapsed multiple myeloma reveals extensive cancer testis antigen expression. Cancer testis antigens are confirmed as useful prognostic markers in newly diagnosed multiple myelomapatients and in relapsed multiple myelomapatients. The HOVON-65/GMMG-HD4 trial is registered under Dutch trial register n. NTR-213. CREST, SUMMIT and APEX trials were registered under ns. M34100-024, M34100-025 and NCT00049478/NCT00048230, respectively.
Authors: Annemiek Broyl; Dirk Hose; Henk Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; H Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld Journal: Blood Date: 2010-06-23 Impact factor: 22.113
Authors: D Joseph-Pietras; Y Gao; N Zojer; K Ait-Tahar; A H Banham; K Pulford; J Rice; N Savelyeva; S S Sahota Journal: Leukemia Date: 2010-09-23 Impact factor: 11.528
Authors: Marija Pastorcic-Grgic; Bozena Sarcevic; Danijel Dosen; Antonio Juretic; Giulio C Spagnoli; Marko Grgic Journal: Head Neck Date: 2010-09 Impact factor: 3.147
Authors: Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt Journal: Haematologica Date: 2010-09-30 Impact factor: 9.941
Authors: Monika Engelhardt; Josefina Udi; Martina Kleber; Andrew Spencer; Alberto Rocci; Stefan Knop; Benedetto Bruno; Sara Bringhen; José A Pérez-Simón; Sonja Zweegman; Christoph Driessen; Francesca Patriarca; Martin Gramatzki; Evangelos Terpos; Orhan Sezer; Martin Kropff; Christian Straka; Hans E Johnsen; Anders Waage; Martin Boegsted; Henk Lokhorst; Roman Hájek; Gareth Morgan; Mario Boccadoro; Heinz Ludwig; Michele Cavo; Aaron Polliack; Pieter Sonneveld; Hermann Einsele; Antonio Palumbo Journal: Leuk Lymphoma Date: 2010-08-31
Authors: Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao Journal: Cancer Immunol Res Date: 2013-11-25 Impact factor: 11.151
Authors: Leticia Y Peche; María F Ladelfa; María F Toledo; Miguel Mano; Julieta E Laiseca; Claudio Schneider; Martín Monte Journal: J Biol Chem Date: 2015-10-14 Impact factor: 5.157
Authors: Edward A Stadtmauer; Thomas H Faitg; Daniel E Lowther; Ashraf Z Badros; Karen Chagin; Karen Dengel; Malini Iyengar; Luca Melchiori; Jean-Marc Navenot; Elliot Norry; Trupti Trivedi; Ruoxi Wang; Gwendolyn K Binder; Rafael Amado; Aaron P Rapoport Journal: Blood Adv Date: 2019-07-09
Authors: M A Rosenzweig; H Landau; D Seldin; C O'Hara; S Girnius; N Hanson; D Frosina; C Sedrak; M Arcila; R L Comenzo; S Giralt; S Gnjatic; A A Jungbluth; G Koehne Journal: Blood Cancer J Date: 2012-09-14 Impact factor: 11.037